Equities research analysts at Cantor Fitzgerald began coverage on shares of Okta (NASDAQ:OKTA – Get Free Report) in a report released on Monday, Marketbeat.com reports. The brokerage set an ...

Cantor Fitzgerald has a “Overweight” rating and a $7.00 price objective on the stock. The consensus estimate for Mereo BioPharma Group’s current full-year earnings is ($0.03) per share.

March 31 (Reuters) - Analysts at Cantor Fitzgerald, formerly headed by the Trump administration's Secretary of Commerce Howard Lutnick, called for the dismissal of Secretary of Health and Human ...

(Reuters) - Analysts at Cantor Fitzgerald, formerly headed by the Trump administration's Secretary Of Commerce Howard Lutnick, called for the dismissal of Secretary of Health and Human Services Robert ...

Cantor Fitzgerald biotech analysts slammed the leadership of Health and Human Services Secretary Robert F. Kennedy Jr., calling on the Trump administration to “re-evaluate” his role after a ...

On Wednesday, Cantor Fitzgerald outlined a strategic approach for investors in the smid cap biotech sector, emphasizing the importance of downside protection and the potential for significant upside.

On Tuesday, Cantor Fitzgerald released a new report on the semiconductor and semiconductor equipment sector, highlighting the current geopolitical challenges that are impacting the industry ...

Analysts at Cantor, Formerly Headed by Lutnick, Call for Kennedy's Dismissal (Reuters) - Analysts at Cantor Fitzgerald, formerly headed by the Trump administration's Secretary of Commerce Howard ...